[Skip to Content]
[Skip to Content Landing]
Views 1,267
Citations 0
Original Investigation
November 27, 2019

Economic Evaluation of Brief Cognitive Behavioral Therapy vs Treatment as Usual for Suicidal US Army Soldiers

Author Affiliations
  • 1Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
  • 2Department of Psychology, Harvard University, Cambridge, Massachusetts
  • 3Psychological Health Center of Excellence, Research and Development Directorate (J-9), Defense Health Agency, Silver Spring, Maryland
  • 4Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
  • 5Department of Psychiatry, University of Colorado School of Medicine, Aurora
  • 6Rocky Mountain Mental Illness Research, Education, and Clinical Center, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado
  • 7Department of Psychology, Florida State University, Tallahassee
  • 8National Center for Veterans Studies, University of Utah, Salt Lake City
  • 9Department of Psychology, University of Memphis, Memphis, Tennessee
  • 10Department of Psychology, University of Utah, Salt Lake City
JAMA Psychiatry. Published online November 27, 2019. doi:https://doi.org/10.1001/jamapsychiatry.2019.3639
Key Points

Question  Is brief cognitive behavioral therapy cost-effective vs treatment as usual for preventing suicidal behaviors among at-risk US Army soldiers?

Findings  In this economic evaluation, data from a published clinical trial and multiple epidemiologic data sets were used to estimate that brief cognitive behavioral therapy may be cost saving compared with treatment as usual. Brief cognitive behavioral therapy remained cost-effective in sensitivity analyses that explored alternative scenarios.

Meaning  Brief cognitive behavioral therapy appears to be a cost-effective intervention for at-risk soldiers and should be considered for widespread implementation.

Abstract

Importance  Brief cognitive behavioral therapy (BCBT) is a clinically effective intervention for reducing risk of suicide attempts among suicidal US Army soldiers. However, because specialized treatments can be resource intensive, more information is needed on costs and benefits of BCBT compared with existing treatments.

Objective  To evaluate the cost-effectiveness of BCBT compared with treatment as usual for suicidal soldiers in the US Army.

Design, Setting, and Participants  A decision analytic model compared effects and costs of BCBT vs treatment as usual from a US Department of Defense (DoD) perspective. Model input data were drawn from epidemiologic data sets and a clinical trial among suicidal soldiers conducted from January 31, 2011, to April 3, 2014. Data were analyzed from July 3, 2018, to March 25, 2019.

Interventions  The strategies compared were treatment as usual alone vs treatment as usual plus 12 individual BCBT sessions. Treatment as usual could include a range of pharmacologic and psychological treatment options.

Main Outcomes and Measures  Costs in 2017 US dollars, suicide attempts averted (self-directed behavior with intent to die, but with nonfatal outcome), suicide deaths averted, and incremental cost-effectiveness ratios, assuming a 2-year time horizon for treatment differences but including lifetime costs.

Results  In the base-case analysis, BCBT was expected to avert approximately 23 to 25 more suicide attempts and 1 to 3 more suicide deaths per 100 patients treated than treatment as usual. Sensitivity analyses assuming a range of treatment effects showed BCBT to be cost saving in most scenarios. Using the federal discount rate, the DoD was estimated to save from $15 000 to $16 630 per patient with BCBT vs treatment as usual. In a worst-case scenario (ie, assuming the weakest plausible BCBT effect sizes), BCBT cost an additional $1910 to $2250 per patient compared with treatment as usual.

Conclusions and Relevance  Results suggest BCBT may be a cost-saving intervention for suicidal active-duty soldiers. The costs of ensuring treatment fidelity would also need to be considered when assessing the implications of disseminating BCBT across the entire DoD.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×